Multi-omics analyses of glucose metabolic reprogramming in colorectal cancer
Glucose metabolic reprogramming (GMR) is a cardinal feature of carcinogenesis and metastasis. However, the underlying mechanisms have not been fully elucidated. The aim of this study was to profile the metabolic signature of primary tumor and circulating tumor cells from metastatic colorectal cancer...
Saved in:
Published in | Frontiers in immunology Vol. 14; p. 1179699 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
05.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Glucose metabolic reprogramming (GMR) is a cardinal feature of carcinogenesis and metastasis. However, the underlying mechanisms have not been fully elucidated. The aim of this study was to profile the metabolic signature of primary tumor and circulating tumor cells from metastatic colorectal cancer (mCRC) patients using integrated omics analysis.
PET-CT imaging, serum metabolomics, genomics and proteomics data of 325 high 18F-fluorinated deoxyglucose (FDGhigh) mCRC patients were analyzed. The para-tumor, primary tumor and liver metastatic tissues of mCRC patients were used for proteomics analysis.
The glucose uptake in tumor tissues as per the PET/CT images was correlated to serum levels of glutamic-pyruvic transaminase (ALT), total bilirubin (TBIL), creatinine (CRE). Proteomics analysis indicated that several differentially expressed proteins were enriched in both GMR and epithelial-mesenchymal transition (EMT)-related pathways. Using a tissue-optimized proteomic workflow, we identified novel proteomic markers (e.g. CCND1, EPCAM, RPS6), a novel PCK1-CDK6-INSR protein axis, and a potential role for FOLR (FR) in GMR/EMT of CRC cells. Finally, CEA/blood glucose (CSR) was defined as a new index, which can be used to jointly diagnose liver metastasis of colorectal cancer.
GMR in CRC cells is closely associated with the EMT pathway, and this network is a promising source of potential therapeutic targets. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Simona Kranjc Brezar, Department of Experimental Oncology, Slovenia These authors share first authorship Reviewed by: Yoichi Takakusagi, National Institutes for Quantum and Radiological Science and Technology, Japan; Kishor Pant, University of Minnesota Twin Cities, United States; Francesca Nazio, University of Rome Tor Vergata, Italy |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2023.1179699 |